Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 22536-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#22536-1-AP, RRID:AB_11232419
- Product name
- WDR61 antibody
- Antibody type
- Polyclonal
- Description
- WDR61 antibody (Cat. #22536-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Inherited blood cancer predisposition through altered transcription elongation.
ARF alters PAF1 complex integrity to selectively repress oncogenic transcription programs upon p53 loss.
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer.
WDR61 ablation triggers R-loop accumulation and suppresses breast cancer progression.
FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.
SPT6 functions in transcriptional pause/release via PAF1C recruitment.
UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer.
Zhao J, Cato LD, Arora UP, Bao EL, Bryant SC, Williams N, Jia Y, Goldman SR, Nangalia J, Erb MA, Vos SM, Armstrong SA, Sankaran VG
Cell 2024 Feb 1;187(3):642-658.e19
Cell 2024 Feb 1;187(3):642-658.e19
ARF alters PAF1 complex integrity to selectively repress oncogenic transcription programs upon p53 loss.
Wang J, Fendler NL, Shukla A, Wu SY, Challa A, Lee J, Joachimiak LA, Minna JD, Chiang CM, Vos SM, D'Orso I
Molecular cell 2024 Dec 5;84(23):4538-4557.e12
Molecular cell 2024 Dec 5;84(23):4538-4557.e12
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer.
Triboulet R, Sadykov K, Harvey DM, Wilson DM, Steinbaugh MJ, Mayo CB, Hawley D, Madanjian A, Fyfe C, Bracken C, Rivera-Rivera I, Ericsson A, Snyder AR, Knutson SK, Stein RL, Gibaja V, Ghosh S, Campbell RM
Molecular cancer therapeutics 2024 Dec 3;23(12):1779-1788
Molecular cancer therapeutics 2024 Dec 3;23(12):1779-1788
WDR61 ablation triggers R-loop accumulation and suppresses breast cancer progression.
Hou Y, Zhang C, Liu L, Yu Y, Shi L, Qin Y
The FEBS journal 2024 Aug;291(15):3417-3431
The FEBS journal 2024 Aug;291(15):3417-3431
FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.
Liu Y, Yu K, Kong X, Zhang K, Wang L, Zhang N, Chen Q, Niu M, Li W, Zhong X, Wu S, Zhang J, Liu Y
Science advances 2023 Aug 18;9(33):eadg7112
Science advances 2023 Aug 18;9(33):eadg7112
SPT6 functions in transcriptional pause/release via PAF1C recruitment.
Aoi Y, Shah AP, Ganesan S, Soliman SHA, Cho BK, Goo YA, Kelleher NL, Shilatifard A
Molecular cell 2022 Sep 15;82(18):3412-3423.e5
Molecular cell 2022 Sep 15;82(18):3412-3423.e5
UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer.
Xiang G, Wang S, Chen L, Song M, Song X, Wang H, Zhou P, Ma X, Yu J
Cell death & disease 2022 May 12;13(5):451
Cell death & disease 2022 May 12;13(5):451
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The WDR61 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human WDR61. This antibody recognizes human, mouse, rat antigen. The WDR61 antibody has been validated for the following applications: ELISA, WB analysis.
